Bright Ideas - CIN Feasibility Study

Description

In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.

Conditions

Acute Lymphoblastic Leukemia (ALL)

Talk to us

Study Overview

On this page

Study Details

Study overview

In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.

Improving Chemotherapy-induced Nausea Control Through Bright Ideas®-CIN Training: a Feasibility Study in Children Receiving Oral Chemotherapy

Bright Ideas - CIN Feasibility Study

Condition
Acute Lymphoblastic Leukemia (ALL)
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Children's Hospital Los Angeles, Los Angeles, California, United States, 90027

New Brunswick

Rutgers Cancer Institute, New Brunswick, New Jersey, United States, 08901

Falls Church

Inova Children's Hospital, Falls Church, Virginia, United States, 22042

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age: ≥ 4 years (PeNAT validated in patients 4 to 18 yrs)
  • * newly diagnosed or recurrent disease: first diagnosis of ALL (i.e. non-relapsed) in maintenance therapy
  • * English, French or Spanish-speaking with an English, French or Spanish-speaking guardian (PeNAT available in these languages)
  • * without physical or cognitive impairments that preclude use of the PeNAT
  • * planned to receive PO 6-mercaptopurine
  • * not planned to receive IV, IM, SC or IT chemotherapy or oral or IV corticosteroids during the 7-day study period

Ages Eligible for Study

4 Years to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Hospital for Sick Children,

Lee Dupuis, PhD, PRINCIPAL_INVESTIGATOR, SickKids Research Institute

Study Record Dates

2025-06